Deltagen, Inc. is a provider of drug discovery tools and services to the biopharmaceutical industry. The Company offers a suite of programs designed to manage the efficiency of drug discovery, including access to biological models, as well as both small-molecule and secreted protein drug targets. In addition, it offers target validation data in the areas of immunology and metabolic diseases. The Company's biology approach is designed to help clear lead validation hurdle of drug target discovery. Its DeltaBase is a searchable database of in vivo-derived mammalian gene function information and gene targets. DeltaOne from the Company provides per-gene access to the knockout mice and/or phenotypic data needed.
Revenue (Most Recent Fiscal Year) | -- |
Net Income (Most Recent Fiscal Year) | -- |
PE Ratio (Current Year Earnings Estimate) | -- |
PE Ratio (Trailing 12 Months) | -- |
PEG Ratio (Long Term Growth Estimate) | -- |
Price to Sales Ratio (Trailing 12 Months) | -- |
Price to Book Ratio (Most Recent Quarterly Book Value per Share) | -- |
Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
Pre-Tax Margin (Trailing 12 Months) | -- |
Net Margin (Trailing 12 Months) | -- |
Return on Equity (Trailing 12 Months) | -- |
Return on Assets (Trailing 12 Months) | -- |
Current Ratio (Most Recent Fiscal Quarter) | -- |
Quick Ratio (Most Recent Fiscal Quarter) | -- |
Debt to Common Equity (Most Recent Fiscal Quarter) | -- |
Inventory Turnover (Trailing 12 Months) | -- |
Book Value per Share (Most Recent Fiscal Quarter) | -- |
Earnings per Share (Most Recent Fiscal Quarter) | -- |
Earnings per Share (Most Recent Fiscal Year) | -- |
Diluted Earnings per Share (Trailing 12 Months) | -- |
Exchange | -- |
Sector | -- |
Industry | -- |
Common Shares Outstanding | -- |
Free Float | -- |
Market Capitalization | -- |
Average Volume (Last 20 Days) | -- |
Beta (Past 60 Months) | -- |
Percentage Held By Insiders (Latest Annual Proxy Report) | 46.00% |
Percentage Held By Institutions (Latest 13F Reports) | 0.00% |
Annual Dividend (Based on Last Quarter) | $0.00 |
Dividend Yield (Based on Last Quarter) | 0.00% |